Posted inCardiology Clinical Updates news Specialties
Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia: Advances in Antisense Therapies for Triglyceride Reduction
Olezarsen, a GalNAc-conjugated antisense oligonucleotide targeting APOC3 mRNA, significantly reduces triglyceride levels in moderate hypertriglyceridemia, offering a promising therapeutic advance with favorable safety in cardiovascular risk patients.